Olema Pharmaceuticals Inc. Insider Trading
OLMA
Insiders sold $24.7M and bought nothing on the open market.
None of the selling was scheduled in advance under a 10b5-1 plan. Director Ian T Clark sold $7.87M on Dec 19, 2025, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Dec 2024.
Get an email when OLMA's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Jul 23 – 24 | Cyrus Harmon Director | SoldNo plan 2 parts | 25,000 | $11.65 average | 291K | 3.0% | Form 4 |
| Mar 3 – 4 | Shawnte Mitchell Chief Legal Officer | SoldNo plan 3 parts | 40,000 | $23.79 average | 952K | 99% | Form 4 |
| Jan 20 | Cyrus Harmon Director | SoldNo plan | 10,000 | $26.88 | 269K | 1.2% | Form 4 |
| Jan 13 – 15 | Shane William Charles Kovacs Ch. Operating & Financial Off. | SoldNo plan 2 parts | 103,822 | $28.70 average | $2.98M | 43% | Form 4 |
| Jan 14 | Cyrus Harmon Director | SoldNo plan | 3,489 | $29.12 | 102K | 0.4% | Form 4 |
| Jan 12 – 14 | David C. Myles Ch. Discov. & Non-clin Dev Off | SoldNo plan 5 parts | 110,000 | $28.25 average | $3.11M | 14% | Form 4 |
| Dec 19, 2025 – Dec 23, 2025 | Naseem Zojwalla Chief Medical Officer | SoldNo plan 4 parts | 269,509 | $27.94 average | $7.53M | 98% | Form 4 |
| Dec 22, 2025 | Cyrus Harmon Director | SoldNo plan | 2,881 | $28.53 | 82K | 0.3% | Form 4 |
| Dec 19, 2025 | David C. Myles Ch. Discov. & Non-clin Dev Off | SoldNo plan 3 parts | 51,000 | $30.46 average | $1.55M | 8.4% | Form 4 |
| Dec 19, 2025 | Ian T Clark Director | SoldNo plan 3 parts | 264,800 | $29.73 average | $7.87M | 100% | Form 4 |
| Sep 16, 2025 – Sep 18, 2025 | Cyrus Harmon Director | SoldNo plan 4 parts | 25,000 | $8.19 average | 205K | 2.8% | Form 4 |
| Jan 8, 2025 | Bain Capital Life Sciences Investors, LLC Large holder | Bought | 300,000 | $5.76 | $1.73M | 7.5% | Form 4 |
| Dec 17, 2024 | G. Walmsley Graham Director | Bought | 700,761 | $6.75 | $4.73M | 33% | Form 4 |
| Dec 17, 2024 | G. Walmsley Graham Director | SoldNo plan | 700,761 | $6.75 | $4.73M | 33% | Form 4 |
| Dec 13, 2024 | G. Walmsley Graham Director | Bought | 700,761 | $6.75 | $4.73M | New | Form 4 |
| Dec 13, 2024 | G. Walmsley Graham Director | SoldNo plan | 700,761 | $6.75 | $4.73M | 50% | Form 4 |
| Dec 10, 2024 – Dec 11, 2024 | Cyrus Harmon Director | SoldNo plan 3 parts | 16,393 | $9.03 average | 148K | 1.8% | Form 4 |
| Dec 10, 2024 – Dec 11, 2024 | David C. Myles Ch. Discov. & Non-clin Dev Off | SoldNo plan 3 parts | 26,066 | $9.01 average | 235K | 3.3% | Form 4 |
| Dec 10, 2024 – Dec 11, 2024 | Naseem Zojwalla Chief Medical Officer | SoldNo plan 3 parts | 27,805 | $9.01 average | 250K | 19% | Form 4 |
| Dec 10, 2024 – Dec 11, 2024 | Shane William Charles Kovacs Ch. Operating & Financial Off. | SoldNo plan 3 parts | 35,159 | $9.01 average | 317K | 6.1% | Form 4 |
| Dec 10, 2024 – Dec 11, 2024 | Sean Bohen President and CEO | SoldNo plan 3 parts | 109,502 | $9.01 average | 986K | 31% | Form 4 |
- Jul 23 – 24No planCyrus HarmonDirector · sold 25,000 at avg $11.65291K3.0% of stake
- Mar 3 – 4No planShawnte MitchellChief Legal Officer · sold 40,000 at avg $23.79952K99% of stake
- Jan 20No planCyrus HarmonDirector · sold 10,000 at $26.88269K1.2% of stake
- Jan 13 – 15No planShane William Charles KovacsCh. Operating & Financial Off. · sold 103,822 at avg $28.70$2.98M43% of stake
- Jan 14No planCyrus HarmonDirector · sold 3,489 at $29.12102K0.4% of stake
- Jan 12 – 14No planDavid C. MylesCh. Discov. & Non-clin Dev Off · sold 110,000 at avg $28.25$3.11M14% of stake
- Dec 19, 2025 – Dec 23, 2025No planNaseem ZojwallaChief Medical Officer · sold 269,509 at avg $27.94$7.53M98% of stake
- Dec 22, 2025No planCyrus HarmonDirector · sold 2,881 at $28.5382K0.3% of stake
- Dec 19, 2025No planDavid C. MylesCh. Discov. & Non-clin Dev Off · sold 51,000 at avg $30.46$1.55M8.4% of stake
- Dec 19, 2025No planIan T ClarkDirector · sold 264,800 at avg $29.73$7.87M100% of stake
- Sep 16, 2025 – Sep 18, 2025No planCyrus HarmonDirector · sold 25,000 at avg $8.19205K2.8% of stake
- Jan 8, 2025Bain Capital Life Sciences Investors, LLCLarge holder · bought 300,000 at $5.76$1.73M7.5% of stake
- Dec 17, 2024G. Walmsley GrahamDirector · bought 700,761 at $6.75$4.73M33% of stake
- Dec 17, 2024No planG. Walmsley GrahamDirector · sold 700,761 at $6.75$4.73M33% of stake
- Dec 13, 2024G. Walmsley GrahamDirector · bought 700,761 at $6.75$4.73MNew position
- Dec 13, 2024No planG. Walmsley GrahamDirector · sold 700,761 at $6.75$4.73M50% of stake
- Dec 10, 2024 – Dec 11, 2024No planCyrus HarmonDirector · sold 16,393 at avg $9.03148K1.8% of stake
- Dec 10, 2024 – Dec 11, 2024No planDavid C. MylesCh. Discov. & Non-clin Dev Off · sold 26,066 at avg $9.01235K3.3% of stake
- Dec 10, 2024 – Dec 11, 2024No planNaseem ZojwallaChief Medical Officer · sold 27,805 at avg $9.01250K19% of stake
- Dec 10, 2024 – Dec 11, 2024No planShane William Charles KovacsCh. Operating & Financial Off. · sold 35,159 at avg $9.01317K6.1% of stake
- Dec 10, 2024 – Dec 11, 2024No planSean BohenPresident and CEO · sold 109,502 at avg $9.01986K31% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with OLMA
Held by ETFs
OLMA is in 29 US ETFs. The largest of them, with OLMA's weight in each:
Spot a number that looks wrong? Check it in OLMA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing OLMA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.